These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 18567397

  • 21. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Warnke C, Adams O, Hartung HP, Kieseier BC.
    Ann Neurol; 2011 Jan; 69(1):215-6; author reply 216. PubMed ID: 21280097
    [No Abstract] [Full Text] [Related]

  • 22. Natalizumab.
    Berger JR.
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [Abstract] [Full Text] [Related]

  • 23. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J.
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [Abstract] [Full Text] [Related]

  • 24. Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
    Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH.
    Ann Neurol; 2010 Sep; 68(3):392-5. PubMed ID: 20661928
    [Abstract] [Full Text] [Related]

  • 25. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 26. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.
    Neurology; 2011 Feb 08; 76(6):574-6. PubMed ID: 21300973
    [No Abstract] [Full Text] [Related]

  • 27. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC, Masjuan J, Villar LM.
    N Engl J Med; 2005 Oct 20; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract] [Full Text] [Related]

  • 28. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep 11; 48(1243):76. PubMed ID: 16977289
    [No Abstract] [Full Text] [Related]

  • 29. [Treatment of multiple sclerosis].
    Holmøy T, Harbo HF, Celius EG.
    Tidsskr Nor Laegeforen; 2010 May 06; 130(9):923; author reply 923. PubMed ID: 20453948
    [No Abstract] [Full Text] [Related]

  • 30. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
    Rice GP, Hartung HP, Calabresi PA.
    Neurology; 2005 Apr 26; 64(8):1336-42. PubMed ID: 15851719
    [Abstract] [Full Text] [Related]

  • 31. Multiple sclerosis and Natalizumab.
    Fiore D.
    Am J Ther; 2007 Apr 26; 14(6):555-60. PubMed ID: 18090880
    [Abstract] [Full Text] [Related]

  • 32. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A.
    BMJ; 2006 Feb 18; 332(7538):416-9. PubMed ID: 16484271
    [Abstract] [Full Text] [Related]

  • 33. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S, Berger JR.
    J Neurol Sci; 2008 Jan 15; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract] [Full Text] [Related]

  • 34. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 15; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 35. PML risk and natalizumab: more questions than answers.
    Ransohoff RM.
    Lancet Neurol; 2010 Mar 15; 9(3):231-3. PubMed ID: 20117056
    [No Abstract] [Full Text] [Related]

  • 36. The return of natalizumab: weighing benefit against risk.
    Goodin D.
    Lancet Neurol; 2006 May 15; 5(5):375-7. PubMed ID: 16632301
    [No Abstract] [Full Text] [Related]

  • 37. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ, Munday JR.
    Drug Discov Today; 2007 Jul 15; 12(13-14):569-76. PubMed ID: 17631252
    [Abstract] [Full Text] [Related]

  • 38. Natalizumab: bound to rebound?
    Schiess N, Calabresi PA.
    Neurology; 2009 Feb 03; 72(5):392-3. PubMed ID: 19188569
    [No Abstract] [Full Text] [Related]

  • 39. [New drugs; natalizumab].
    van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Mar 01; 152(9):499-500. PubMed ID: 18389881
    [Abstract] [Full Text] [Related]

  • 40. [Progressive multifocal leukoencephalopathy after natalizumab therapy].
    Schmitt C, Bensussan A.
    Med Sci (Paris); 2005 Oct 01; 21(10):797-8. PubMed ID: 16197890
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.